Lipicard Technologies Study: Platrol(R) - A Novel Antiplatelet Drug Without a Hole in the Stomach

HYDERABAD, India--(BUSINESS WIRE)--July 31, 2006--All currently available antiplatelet drugs viz- Aspirin, PLAVIX(R), Persantine, Aggrastat, and Ticlid are toxic. The CAPRIE (1996) study showed that the largest selling antiplatelet drugs PLAVIX(R) (Clopidogrel) and Aspirin are quite toxic with over 50% of those who take either of them suffer from various toxic side effects. Of course, the added attraction for PLAVIX(R) is high cost, especially for the non-responders without any effect on platelet aggregation.

Side Effect and complications of PLAVIX(R) (Clopidogrel) & Aspirin respectively (CAPRIE STUDY) are:

-- Incidence of gastrointestinal events: 27.1% PLAVIX(R); 29.8% Aspirin

-- Incidence of skin and appendage disorders: 15.8 % PLAVIX(R); 13.1% Aspirin

-- Cases of diarrhea: 4.5 % PLAVIX(R); 3.4% Aspirin

-- Gastrointestinal hemorrhages: 2.0 % PLAVIX(R); 2.7% Aspirin

-- Gastrointestinal hemorrhage required hospitalization: 0.7 % PLAVIX(R); 1.1% Aspirin

-- Incidence of peptic, gastric or duodenal ulcers: 0.7 % PLAVIX(R); 1.2% Aspirin

-- Incidence of intracranial hemorrhage: 0.4 % PLAVIX(R); 0.5% Aspirin

-- Total incidence of side effects: 51.2% PLAVIX(R); 51.8% Aspirin

Mr. Sambaru Prasad, CEO, Lipicard Technologies said, PLATROL(R) is the first anti-platelet drug, which promises no gastric irritation or related side effects. In gastric mucosa irritation animal toxicology study, 60% of rats were affected with gastric irritation at 200mg/kg and 300mg/kg dose of Aspirin, whereas, PLATROL(R) affected none of the rats in either of those equivalent dosages.

PLATROL(R) was found to be less toxic than Aspirin in the 28-day animal toxicology study as well. A few animals treated with Aspirin showed mild fatty changes in the cardiac muscle fibers of heart and mild catarrhal changes of gastric mucosa, whereas, none of the animals treated with PLATROL(R) showed any such change.

The molecular structure and mechanism of action of PLATROL(R) is responsible for selective antiplatelet activity without the side effect, according to Mr. Prasad.

About Lipicard Technologies

Lipicard Technologies Limited develops innovative and novel High Therapeutic Index Drugs for Lipid management and cardioprotection in collaboration with Life Enhancing Technologies LLC. USA. PLATROL(R) is the first safe antiplatelet drug being developed for cardio-protection. Next in line is the integrated Lipid management drug for increasing HDL and lowering LDL.

PLAVIX(R) and PLATROL(R) are registered trademarks of Sanofi-Synthelabo, and Life Enhancing Technologies respectively.